Traditionally, it is sales figures that add value to pharma companies and this is usually substanciated with quarterly financial reports. I would expect most news we receive in the future (outside of sales contracts) will pop and then retrace some. An announcement of a large retail contract in Canada should add significant value to the company and I would expect that to raise the SP and hold it, however, anything can happen.